Maternal Serum Screening
A step towards early detection of genetic disorders
Prenatal Accuracy
-
Certification of DELFIA Technology: DELFIA is one of the only four biochemistry analysers certified by FMF.
-
Importance of FMF Certification: As per clinical research, non-FMF-certified assays lower the detection rate and increase the false positive rate.
-
Validation of Multiple of Medians (MoMs): MoMs have been validated with indigenous population data.
-
Accreditation Status: CAP and NABL accredited.
Clinical Indications of Maternal Serum Screening
- Pregnant women seeking early assessment of genetic and structural risks.
- Individuals with a family history of aneuploidies.
- Women of advanced maternal age.
- Pregnancies requiring non-invasive risk calculation prior to diagnostic tests.
Specifications
| First Trimester Screening: | β-hCG, PAPP-A |
| First Trimester + Pre-eclampsia Risk: | β-hCG, PAPP-A, PlGF |
| Quadruple Screening: | AFP, β-hCG, uE3, Inhibin A |
| Triple Marker: | AFP, hCG, uE3 |
Maternal Serum Screening Offered by GeneHealth
🧬
First Trimester Screening
- Markers: Free βHCG, PAPP-A
- Gestation: 11W-13W+ 6 days
- TAT: 1 working day
- Test Code: MGM2445
First Trimester Screening + Pre-eclampsia Risk
- Markers: Free βHCG, PAPP-A, PlGF
- Gestation: 11W-13W+ 6 days
- TAT: 3 working days
- Test Code: MGM2447
Key Highlights of GeneHealth’s Screening
Advanced Technology
Offers Maternal Serum Screening using DELFIA® technology, approved by the Fetal Medicine Foundation (FMF – UK).
Tailored Reporting
Reports are optimised based on risk levels (low, intermediate, and high) to ensure clarity for clinicians.
Proactive Monitoring
Prompt warnings by monitoring variations in Multiple of Medians (MoMs) to normalise test results accurately.
